A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach.

IF 4.2 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-09-25 DOI:10.1093/oncolo/oyaf312

Jingru Wang, Jinbo Zhan, Zhen Rao, Gang Su, Yan He, Ling Zhou, Jianhua Wu, Xiaowei Sun, Xiaojun Xiang

{"title":"A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach.","authors":"Jingru Wang, Jinbo Zhan, Zhen Rao, Gang Su, Yan He, Ling Zhou, Jianhua Wu, Xiaowei Sun, Xiaojun Xiang","doi":"10.1093/oncolo/oyaf312","DOIUrl":null,"url":null,"abstract":"Purpose: This study aims to evaluate the efficacy and safety of PD-1 blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS).Materials and methods: This study retrospectively collected data from 25 patients with advanced HAS who received first-line PD-1 blockade combined with chemotherapy across 6 centers between January 2018 and January 2024. Progression-Free Survival (PFS) and Overall Survival (OS) were assessed using Kaplan-Meier (KM) curves.Results: This study included 25 patients with HAS, all of whom received a first-line treatment regimen combining PD-1 blockade and chemotherapy. The Objective Response Rate (ORR) and Disease Control Rate (DCR) were 76.0% and 88.0%, respectively. The median follow-up time was 13.1 months, with a median Progression-Free Survival (mPFS) of 10.2 months (95% CI: 6.3-14.1) and a median Overall Survival (mOS) of 20.3 months (95% CI: 11.3-29.4). A total of 20 patients (80.0%) experienced adverse reactions of varying degrees, with white blood cell (WBC) count decreased (12, 48.0%) being the most common adverse event. Two patients experienced fatal adverse events (grade 5),both of which were unrelated to the PD-1 blockade.Conclusion: Patients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients' PD-L1 combined positive score (CPS).","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf312","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aims to evaluate the efficacy and safety of PD-1 blockade in combination with chemotherapy for patients with advanced hepatoid adenocarcinoma of the stomach (HAS).

Materials and methods: This study retrospectively collected data from 25 patients with advanced HAS who received first-line PD-1 blockade combined with chemotherapy across 6 centers between January 2018 and January 2024. Progression-Free Survival (PFS) and Overall Survival (OS) were assessed using Kaplan-Meier (KM) curves.

Results: This study included 25 patients with HAS, all of whom received a first-line treatment regimen combining PD-1 blockade and chemotherapy. The Objective Response Rate (ORR) and Disease Control Rate (DCR) were 76.0% and 88.0%, respectively. The median follow-up time was 13.1 months, with a median Progression-Free Survival (mPFS) of 10.2 months (95% CI: 6.3-14.1) and a median Overall Survival (mOS) of 20.3 months (95% CI: 11.3-29.4). A total of 20 patients (80.0%) experienced adverse reactions of varying degrees, with white blood cell (WBC) count decreased (12, 48.0%) being the most common adverse event. Two patients experienced fatal adverse events (grade 5),both of which were unrelated to the PD-1 blockade.

Conclusion: Patients with HAS can derive survival benefits from first-line treatment with PD-1 blockade combined with chemotherapy, and the treatment is well tolerated. Furthermore, this pathological subtype may serve as a predictive indicator of favorable efficacy for PD-1 blockade, regardless of the patients' PD-L1 combined positive score (CPS).

查看原文本刊更多论文

PD-1阻断联合化疗作为晚期胃肝样腺癌一线治疗的多中心回顾性研究

目的：本研究旨在评价PD-1阻断联合化疗治疗晚期胃肝样腺癌（HAS）患者的疗效和安全性。材料和方法：本研究回顾性收集了2018年1月至2024年1月期间6个中心接受一线PD-1阻断联合化疗的25例晚期HAS患者的数据。采用Kaplan-Meier （KM）曲线评估无进展生存期（PFS）和总生存期（OS）。结果：本研究纳入了25例HAS患者，所有患者均接受了PD-1阻断联合化疗的一线治疗方案。客观有效率（ORR）和疾病控制率（DCR）分别为76.0%和88.0%。中位随访时间为13.1个月，中位无进展生存期（mPFS）为10.2个月（95% CI: 6.3-14.1），中位总生存期（mOS）为20.3个月（95% CI: 11.3-29.4）。共有20例（80.0%）患者出现不同程度的不良反应，其中最常见的不良反应是白细胞计数下降（12例，48.0%）。两名患者出现了致命的不良事件（5级），这两个事件都与PD-1阻断无关。结论：一线PD-1阻断联合化疗可使HAS患者获得生存获益，且治疗耐受性良好。此外，无论患者的PD-L1联合阳性评分（CPS）如何，这种病理亚型都可以作为PD-1阻断治疗有利疗效的预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.